news
Boehringer Ingelheim broadens its breast cancer trial programme for Afatinib
30 August 2011 | By Boehringer Ingelheim
Two phase II studies investigating afatinib are now open for recruitment...
List view / Grid view
Boehringer Ingelheim
news
Pradaxa® (dabigatran etexilate, 150mg bid) shows significant reduction in the risk of stroke
New data from two RE-LY® trial subgroup analyses show that dabigatran etexilate 150mg bid consistently reduces the risk of stroke in atrial fibrillation (AF) compared to well-controlled warfarin, irrespective of whether patients use antiplatelet [1] or other concomitant therapies, such as the anti-arrhythmics amiodarone or verapamil. [2] The relative benefits…
news
Linagliptin receives approval in Europe for treatment of type 2 diabetes
25 August 2011 | By Eli Lilly and Company, Boehringer Ingelheim
Linagliptin is the only DPP-4 inhibitor to be approved at one dosage strength for adults with type 2 diabetes in Europe, without any need for dose adjustments...
news
Trajenta® (linagliptin) receives approval for the treatment of type 2 diabetes in Europe
25 August 2011 | By Boehringer Ingelheim
Marketing Authorisation from the European Commission for Trajenta® (linagliptin)...
news
Boehringer Ingelheim licenses ProBioGen’s novel GlymaxX® technology
10 August 2011 | By Boehringer Ingelheim
Boehringer Ingelheim and ProBioGen AG have signed a non-exclusive Licensing Agreement regarding ProBioGen’s GlymaxX® technology...
news
Positive first half-year 2011 for Boehringer Ingelheim
9 August 2011 | By Boehringer Ingelheim
The pharmaceutical company Boehringer Ingelheim has in the first half of 2011 once again grown in local currency terms compared to the previous year (+ 4 percent). Due to negative foreign exchange effects, consolidation in euros shows growth of 2.6 percent, with total net sales of EUR 6.4 billion against…
news
PRADAXA® (dabigatran etexilate) first drug in 50 years to gain approval for stroke prevention in atrial fibrillation in Europe
4 August 2011 | By Ogilvy Healthworld UK Limited
Pradaxa®1 (dabigatran etexilate) approved...
news
Viramune® (nevirapine) receives CHMP recommendation for approval
27 July 2011 | By Boehringer Ingelheim
The CHMP issued a Positive Opinion recommending the approval of Viramune® (nevirapine)...
news
Boehringer Ingelheim and Ashoka’s Changemakers launch “Making More Health” competition
6 July 2011 | By Boehringer Ingelheim
The www.changemakers.com/morehealth competition launched...
news
Linagliptin recommended for approval in the treatment of type 2 diabetes
24 June 2011 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly received a positive opinion from the EMA's medicinal committee...
news
Boehringer Ingelheim extends “one stop shop” service
20 June 2011 | By Boehringer Ingelheim
To round off its full-service capabilities for clients, Boehringer Ingelheim is expanding its capacities and capabilities in fill & finish for biopharmaceuticals at their state-of-the-art facility in Biberach, Germany, with a new filling line.
news
New data confirm superior blood pressure reductions in diabetic patients treated with TWYNSTA®
17 June 2011 | By Boehringer Ingelheim
TWYNSTA® leads to prompt and very effective reductions in blood pressure...
news
Boehringer Ingelheim & Zealand Pharma enter into a licence & collaboration agreement
16 June 2011 | By Boehringer Ingelheim
For dual-acting glucagon and GLP-1 receptor agonists...
news
Twelfth milestone payment as part of its discovery alliance with Boehringer Ingelheim received
9 May 2011 | By Evotec AG
Twelfth milestone triggers payment of EUR 2 million to Evotec...
news
FDA approves linagliptin tablets for the treatment of type 2 diabetes
3 May 2011 | By OgilvyHealthPR
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has approved linagliptin tablets, a prescription medication used along with diet and exercise to lower blood sugar in adults with type 2 diabetes.1 The FDA has approved linagliptin as a monotherapy…
